Aviptadil Should Not Be Used for ARDS Management
Aviptadil is not recommended for the treatment of acute respiratory distress syndrome (ARDS) based on current evidence showing no survival benefit and lack of inclusion in established clinical practice guidelines.
Evidence-Based Rationale
The most recent American Thoracic Society clinical practice guideline for ARDS management (2024) 1 provides comprehensive recommendations for ARDS treatment but does not include aviptadil among recommended therapies. The guideline specifically recommends:
- Corticosteroids (conditional recommendation)
- VV-ECMO in selected severe cases (conditional recommendation)
- Neuromuscular blockers in early severe ARDS (conditional recommendation)
- Higher PEEP strategies (conditional recommendation)
- Lung protective ventilation (strong recommendation)
The absence of aviptadil from these evidence-based guidelines is telling, particularly given that the guideline was published in 2024—after the key aviptadil trials were completed.
Clinical Trial Evidence Shows No Benefit
The highest quality randomized controlled trial data demonstrates no significant survival advantage with aviptadil:
- A 2022 multicenter RCT of 196 patients with COVID-19 respiratory failure 2 showed the primary endpoint (alive and free from respiratory failure at day 60) was not statistically significant (OR 1.6,95% CI 0.86-3.11)
- While a secondary analysis suggested improved survival (OR 2.0,95% CI 1.1-3.9, p=0.035), this was not the pre-specified primary outcome and requires cautious interpretation
A 2025 systematic review and meta-analysis 3 definitively concluded: pooled survival OR comparing aviptadil to placebo was 1.01 (95% CI 0.72-1.42, p=0.93), indicating no significant survival benefit. The authors stated that while aviptadil may have physiological effects on oxygenation and inflammation, "current evidence does not indicate a significant survival benefit."
Critical Pitfalls
The FDA drug label information provided 4 is for AVANDIA (rosiglitazone), a diabetes medication—NOT aviptadil. This appears to be a data error and should be disregarded entirely for ARDS management decisions.
Do not confuse physiological improvements (improved PaO2/FiO2 ratios, reduced IL-6) with clinical benefit. The meta-analysis clearly shows these surrogate markers did not translate to improved survival.
Case series showing 88.9% survival 3 are misleading due to selection bias and lack of control groups—the RCT data is what matters for clinical decision-making.
What Should Be Used Instead
Follow the 2024 ATS guideline recommendations 1:
- Lung protective ventilation (tidal volume 4-8 mL/kg PBW, plateau pressure <30 cm H2O) - strong recommendation
- Prone positioning for >12 hours daily in severe ARDS - strong recommendation 5
- Corticosteroids - conditional recommendation with moderate certainty evidence 1
- Higher PEEP strategies without prolonged recruitment maneuvers in moderate-severe ARDS 1
- Neuromuscular blockade in early severe ARDS - conditional recommendation 1
Prioritize mortality, morbidity, and quality of life outcomes over surrogate physiological endpoints. The evidence clearly demonstrates aviptadil does not improve these patient-centered outcomes in ARDS.